OXYCYTE®

Oxycyte is the company’s perfluorocarbon (PFC) therapeutic oxygen carrier.  It is designed to enhance oxygen delivery to damaged tissues.  When used as an intravenous emulsion, Oxycyte can carry as much as five times more oxygen than hemoglobin, making it an effective means of transporting oxygen to tissues and carrying carbon dioxide to the lungs for disposal.  Oxycyte is not a blood substitute.  Because it is a PFC, and not based on hemoglobin, it does not have the safety issues associated with hemoglobin-based products.  In fact, there have been no adverse events in company clinical trials that were related to Oxycyte.

The chart below summarizes the advantages of Oxycyte.

The company believes Oxycyte has the potential for use in multiple indications, including traumatic brain injury, sickle-cell pain crisis, decompression sickness, stroke, heart attack, and wound treatment. The company estimates that the combined annual incidence for these indications in the United States and Europe is more than 12 million.